MADRIGAL PHARMACEUTICALS INC
MDGLNASDAQTrading Snapshot
- Day Range
- $425.30 – $437.18
- 52-Week Range
- $393.61 – $615.00
- Volume (shares)
- 297,522
- Avg Volume (shares)
- —
- Shares Outstanding
- 23.1M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $958M
- Last Q Revenue
- $364M
- P/E Ratio
- —
- P/S Ratio
- 7.9x
- EPS (TTM)
- $-12.87
- Dividend Yield
- —
- Dilution (1yr)
- +2.3%
MADRIGAL PHARMACEUTICALS INC
MDGL
StockOtter · stockotter.spaceAbout MADRIGAL PHARMACEUTICALS INC
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in c
Baron Health Care Fund: Q3 2026 New Positions And Exits
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
Madrigal Pharmaceuticals is transitioning from hypergrowth to a self-funding franchise, with Rezdiffra now covering enterprise costs ahead of key 2027 data. Q2 net sales grew 71% to $364.3M, with over 50,000 patients on
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis